Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence

Despite earlier detection and recent advances in surgery and radiation, prostate cancer is second only to lung cancer in male cancer deaths in the United States. Hormone therapy in the form of medical or surgical castration remains the mainstay of systemic treatment in prostate cancer. Over the last 15 years with the clinical use of prostate specific antigen (PSA), there has been a shift to using hormone therapy earlier in the disease course and for longer duration. Despite initial favorable response to hormone therapy, over a period of time these tumors will develop androgen‐independence that results in death. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to its response to hormone therapy. Analyses have shown that AR continues to be expressed in androgen‐independent tumors and AR signaling remains intact as demonstrated by the expression of the AR regulated gene, PSA. Androgen‐independent prostate cancers have demonstrated a variety of AR alterations that are either not found in hormone naïve tumors or found at lower frequency. These changes include AR amplification, AR point mutation, and changes in expression of AR co‐regulatory proteins. These AR changes result in a “super AR” that can respond to lower concentrations of androgens or to a wider variety of agonistic ligands. There is also mounting evidence that AR can be activated in a ligand independent fashion by compounds such as growth factors or cytokines working independently or in combination. These growth factors working through receptor tyrosine kinase pathways may promote AR activation and growth in low androgen environments. The clinical significance of these AR alterations in the development and progression of androgen‐independent prostate cancer remains to be determined. Understanding the changes in AR signaling in the evolution of androgen‐independent prostate cancer will be key to the development of more effective hormone therapy. © 2003 Wiley‐Liss, Inc.

[1]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Yeh,et al.  Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells* , 2003, Journal of Biological Chemistry.

[3]  D. Neal,et al.  Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development , 2003, Oncogene.

[4]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[5]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[6]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[7]  O. P. Luzardo,et al.  Transition to androgen-independence in prostate cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. R. Ely,et al.  A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. , 2002, Endocrinology.

[10]  C. Heinlein,et al.  Androgen receptor (AR) coregulators: an overview. , 2002, Endocrine reviews.

[11]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[12]  V. Reuter,et al.  HER‐2 profiling and targeting in prostate carcinoma , 2002, Cancer.

[13]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[14]  M. Kattan,et al.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.

[15]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[16]  E. Small,et al.  Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. , 2001, Seminars in oncology.

[17]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[18]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[19]  H. Scher,et al.  Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Sutherland,et al.  Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. , 2001, Cancer research.

[22]  T. Tammela,et al.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.

[23]  M. A. Carrondo,et al.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. , 2000, The Journal of biological chemistry.

[24]  P. Walsh.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.

[25]  Y. Kubota,et al.  Fluorescence in situ hybridization evaluation of c‐myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients , 2000, The Prostate.

[26]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[27]  G. Prins,et al.  Molecular biology of the androgen receptor. , 2000, Mayo Clinic proceedings.

[28]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[29]  D. Budman,et al.  Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. , 1999, Biochemical and biophysical research communications.

[30]  G. Bubley,et al.  High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.

[31]  Heikki Lehväslaiho,et al.  The Androgen Receptor Gene Mutations Database , 1998, Nucleic Acids Res..

[32]  L. Schwartz,et al.  Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[34]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[36]  E. Small,et al.  Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Gumerlock,et al.  Human androgen receptor expression in prostate cancer following androgen ablation. , 1997, European urology.

[38]  E. Wilson,et al.  Reduced androgen receptor gene expression with first exon CAG repeat expansion. , 1996, Molecular endocrinology.

[39]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Bruce Gottlieb,et al.  The androgen receptor gene mutations database , 1996, Nucleic Acids Res..

[41]  G. Jenster,et al.  Androgen receptor mutations , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[43]  G. Coetzee,et al.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.

[44]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[45]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[46]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[47]  K. Fischbeck,et al.  Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. , 1994, Biochemical and biophysical research communications.

[48]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  T. H. van der Kwast,et al.  Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. , 1992, Biochemistry.

[50]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Nelson,et al.  Triplet repeat mutations in human disease. , 1992, Science.

[52]  J. Griffin.  Androgen resistance--the clinical and molecular spectrum. , 1992, The New England journal of medicine.

[53]  T. H. van der Kwast,et al.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.

[54]  T. H. van der Kwast,et al.  Androgen receptor expression in human tissues: an immunohistochemical study. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[55]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[56]  J. Trapman,et al.  The N-terminal domain of the human androgen receptor is encoded by one, large exon , 1989, Molecular and Cellular Endocrinology.

[57]  J. A. van der Korput,et al.  The human androgen receptor: domain structure, genomic organization and regulation of expression. , 1989, Journal of steroid biochemistry.

[58]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[59]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.